Testing two doses of everolimus for neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed neuroendocrine tumor (NET) that is well-differentiated (low or intermediate grade) and started in the gastrointestinal tract, pancreas, lung, or unknown origin.
- Your cancer is advanced (spread or cannot be removed by surgery) and can be seen on scans.
- Your disease has gotten worse in the last 6 months (as shown by scans).
- You have already tried at least one other type of cancer treatment (stopped more than 3 weeks ago).
- You are in fairly good overall health (ECOG score 0-2) and your blood counts, liver, and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
This trial tests a combination of two drugs—everolimus, which may slow cancer growth, and a PD-1 inhibitor, which helps the immune system fight cancer—for people with advanced colorectal cancer that has progressed after standard treatments. The goal is to see if the combination can shrink or control the cancer.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.